Table 1.
The Characteristics of 647 Patients With NSCLC and 266 Patients With NSCLC Who Developed BMs
| Patient Characteristics | ||||
|---|---|---|---|---|
| NSCLC | EGFR mutated (n = 252) | EGFR wildtype (n = 395) | All (N = 647) | |
| N (%) | N (%) | N | P | |
| Age at diagnosis, years | ||||
| Median | 63.8 ± 9.7 | 64.1 ± 10.3 | 64.0 ± 10.1 | |
| Female | 108 (42.9) | 136 (27.5) | ||
| Male | 144 (57.1) | 259 (72.5) | ||
| EGFR mutation | ||||
| Ex19Del | 128 (50.7) | |||
| L858R | 120 (47.6) | |||
| Uncommon mutation | 4 (1.70) | |||
| NSCLC with BM | EGFR mutated (n = 127) | EGFR wildtype (n = 139) | All (N = 266) | |
| N (%) | N (%) | N | P | |
| Age at diagnosis, years | ||||
| Median | 63.0 ± 9.98 | 60.9 ± 10.4 | 61.9 ± 10.2 | |
| Female | 75 (60.4) | 49 (39.5) | 124 | |
| Male | 52 (36.6) | 90 (63.4) | 142 | <.001 |
| Stage at diagnosis | ||||
| I–III | 36 (50.7) | 35 (49.3) | 71 | |
| IV | 91 (46.7) | 104 (53.3) | 195 | |
| ECOG performance status | ||||
| 0–1 | 108 | 123 | 231 | |
| 2–4 | 18 | 16 | 34 | |
| Number of brain metastases | ||||
| 1–3 | 37 | 50 | 87 | |
| 4–20 | 23 | 19 | 42 | |
| >20 | 5 | 5 | 10 | |
| Tissue type | ||||
| Adenocarcinoma | 122 | 110 | 232 | |
| Squamous cell carcinoma | 4 | 21 | 25 | |
| Large cell neuroendocrine carcinoma | 0 | 2 | 2 | |
| Pleomorphic cell carcinoma | 0 | 5 | 5 | |
| NSCLC (unclassified) | 1 | 1 | 2 | |
| EGFR mutation | ||||
| Ex19Del | 57 (44.9) | |||
| L858R | 67 (52.8) | |||
| Uncommon mutation | 3 (0.24) | |||
| Treatment for BM by | ||||
| EGFR-TKI | 96 (75.6) | |||
| Gefitinib | 69 (54.3) | |||
| Erlotinib | 79 (62.2) | |||
| Afatinib | 22 (17.3) | |||
| Osimertinib | 11 (8.7) | |||
| Operation | 8 (6.3) | 19 (13.7) | 27 | .047 |
| SRS | 68 (53.5) | 83 (59.7) | 151 | |
| WBRT | 38 (30.0) | 54 (38.8) | 92 | |
| ICI | 5 (4.0) | 10 (7.1) | 15 | |
EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; Ex19del, exon 19 deletion; TKIs, tyrosine kinase inhibitors; SRS, stereotactic radiosurgery; WBRT, whole-brain radiation therapy; ICIs, immune checkpoint inhibitors; BMs, brain metastases.